Conference Overview

Unveiling the Most Recent Advancements in Vaccines R&D

The Vaccines R&D 2024 conference is set to serve as a dynamic platform, fostering interdisciplinary collaboration at the cutting edge of accelerated and essential vaccine research. Across a span of three days, distinguished speakers from around the world, representing industry, academia, federal bodies, and regulatory agencies, will share groundbreaking advancements, address contemporary challenges, and provide inspirational insights and innovative lessons gained during the vaccine development process.

More Info

Why Choose Us!

The Prime Gathering for Global Vaccine R&D Community

2750+

Attendees

Our conference has attracted and served over 2750 participants, creating valuable networking opportunities and collaborations

10

Years Experience

A decade of experience in conference organization, delivering seamlessly executed events that foster knowledge sharing and networking excellence

935

Speakers

Vaccines R&D has hosted and engaged with over 900 distinguished speakers, enriching our events with diverse expertise and insights

The Highlighting Part Of Our Program

The conference explores a wide range of topics and sessions, delving into the following areas:

Technology & Delivery Platforms

mRNA, Vector-based, Nanoparticle vaccines, Adjuvants and Emerging technologies

RSV, Influenza, COVID-19

RSV, Influenza, COVID-19, Pneumococcal, Tuberculosis, Whooping cough

Vaccine Development

Preclinical studies, Clinical trials, Regulatory review, Manufacturing, Quality control, Post-market surveillance

Immune Characterization

Antibody production, Neutralization assays, Immune markers, Cytokine profiles, mAbs

New and Emerging

Zika, Ebola, Marburg, Lassa fever, Dengue

Bacterial and Viral

DTP, Pneumococcal, Meningococcal, MMR, Hepatitis, HPV, Chickenpox

Conjugate Vaccines

Recombinant, Polysaccharide, Subunit vaccines

Manufacturing and Regulatory

Antigen production, Formulation, QC, Scale-Up, Cold Chain management

Role of Adjuvants

Immune response, Duration of protection, Vaccine efficacy, Subunit vaccines

Cancer, HIV

Preventive, Therapeutic vaccines, Tumor antigens

Vaccine Safety

Preclinical testing, Adverse event reporting, Regulatory approval, Vaccine hesitancy

Clinical Trials

Phase I, II and III studies

Gallery

2023 Conference Highlights

01

Academics & Researchers

For the individuals

  • Access to all talks and posters
  • Conference material
  • Hot buffet lunch, tea / coffee breaks
  • WiFi in meeting rooms
  • Networking and drinks

$1049

Register

02

Federal

For the individuals

  • Access to all talks and posters
  • Conference material
  • Hot buffet lunch, tea / coffee breaks
  • WiFi in meeting rooms
  • Networking and drinks

$1299

Register

03

Biotech & Pharma

For the individuals

  • Access to all talks and posters
  • Conference material
  • Hot buffet lunch, tea / coffee breaks
  • WiFi in meeting rooms
  • Networking and drinks

$1499

Register

04

Service Providers

For the individuals

  • Access to all talks and posters
  • Conference material
  • Hot buffet lunch, tea / coffee breaks
  • WiFi in meeting rooms
  • Networking and drinks

$1599

Register
Testimonial

What Our Clients Say!